• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Annexon Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    11/10/25 4:08:28 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ANNX alert in real time by email
    8-K
    false000152811500015281152025-11-102025-11-10

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    Pursuant to Section 13 OR 15(d)

    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): November 10, 2025

     

     

    ANNEXON, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

    001-39402

    27-5414423

    (State or other jurisdiction

    (Commission

    (IRS Employer

    of incorporation)

    File Number)

    Identification No.)

     

     

    1400 Sierra Point Parkway, Bldg C, Suite 200

    Brisbane, California 94005

    (Address of principal executive offices) (Zip Code)

     

    Registrant’s telephone number, including area code: (650) 822-5500

    Not Applicable

    (Former name or former address, if changed since last report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

    Trading

    Symbol(s)

    Name of each exchange

    on which registered

    Common Stock, par value $0.001 per share

    ANNX

    The Nasdaq Stock Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On November 10, 2025, Annexon, Inc. (the “Company”) announced certain financial results for the third quarter ended September 30, 2025. A copy of the Company’s press release, titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

    The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

    Item 9.01. Financial Statements and Exhibits.

    (d)
    Exhibits.

     

    Exhibit

     

    Description

     

     

     

    99.1

     

    Press Release, dated November 10, 2025, titled “Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones”

    104

     

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: November 10, 2025

    Annexon, Inc.

    By:

    /s/ Jennifer Lew

    Jennifer Lew

    Executive Vice President and Chief Financial Officer

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     


    Get the next $ANNX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANNX

    DatePrice TargetRatingAnalyst
    3/1/2024$11.00Neutral → Overweight
    JP Morgan
    12/21/2023$4.00 → $6.00Neutral → Buy
    BofA Securities
    10/30/2023$11.00Overweight
    Wells Fargo
    5/26/2023$8.00 → $3.00Buy → Neutral
    BofA Securities
    5/25/2023$19.00 → $9.00Overweight → Neutral
    JP Morgan
    9/16/2022$12.00Buy
    Jefferies
    9/9/2022$15.00Buy
    BTIG Research
    11/30/2021$40.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $ANNX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Annexon Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million

    BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ("Annexon") (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the closing of its previously announced underwritten public offering of 29,423,075 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 4,326,922 additional shares of common stock, at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase

    11/14/25 4:01:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants

    BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. ("Annexon") (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced the pricing of its previously announced underwritten public offering of 25,096,153 shares of its common stock at a price to the public of $2.60 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 3,750,000 shares of common stock at a purchase price of $2.599 per share, which equals the public offering price per share of the common stock less the $0.001 exercis

    11/12/25 10:55:39 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

    BRISBANE, Calif., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing complement-mediated diseases of the body, brain, and eye, today announced that it has commenced an underwritten public offering of $75 million of shares of its common stock or pre-funded warrants to purchase shares of its common stock in lieu thereof. All of the securities are being offered by Annexon. In addition, Annexon expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. The proposed offering is subject to market and

    11/12/25 4:12:38 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Satter Muneer A bought $3,600,784 worth of shares (822,613 units at $4.38) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    11/21/25 9:52:02 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Satter Muneer A bought $5,055,000 worth of shares (1,500,000 units at $3.37) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    11/19/25 9:00:05 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $13,045 worth of shares (4,115 units at $3.17), increasing direct ownership by 10% to 46,175 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    10/31/25 4:15:07 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by Annexon Inc.

    SCHEDULE 13D/A - Annexon, Inc. (0001528115) (Subject)

    11/21/25 7:27:18 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Annexon Inc.

    8-K - Annexon, Inc. (0001528115) (Filer)

    11/14/25 4:41:09 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Annexon Inc.

    424B5 - Annexon, Inc. (0001528115) (Filer)

    11/13/25 4:52:25 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Annexon upgraded by JP Morgan with a new price target

    JP Morgan upgraded Annexon from Neutral to Overweight and set a new price target of $11.00

    3/1/24 7:27:25 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon upgraded by BofA Securities with a new price target

    BofA Securities upgraded Annexon from Neutral to Buy and set a new price target of $6.00 from $4.00 previously

    12/21/23 6:41:39 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Annexon with a new price target

    Wells Fargo initiated coverage of Annexon with a rating of Overweight and set a new price target of $11.00

    10/30/23 7:48:24 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Satter Muneer A bought $3,600,784 worth of shares (822,613 units at $4.38) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    11/21/25 9:52:02 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Satter Muneer A bought $5,055,000 worth of shares (1,500,000 units at $3.37) (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    11/19/25 9:00:05 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $13,045 worth of shares (4,115 units at $3.17), increasing direct ownership by 10% to 46,175 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    10/31/25 4:15:07 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Leadership Updates

    Live Leadership Updates

    View All

    Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Tanruprubart (formerly ANX005) for GBS Advancing Through Regulatory Interactions; MAA Submission in Europe Anticipated in First Quarter of 2026; Ongoing Discussions with FDA Regarding Generalizability Package to Support a BLA Accelerated Completion of Enrollment for Global Phase 3 ARCHER II Trial of Vonaprument (formerly ANX007) for Dry AMD with GA; Selected for EMA PRIME Product Development Candidate Pilot; Topline ARCHER II Data Expected in Second Half of 2026 ANX1502 First-in-Kind Oral C1s Inhibitor Exposure Exceeded Target Concentration in Fasted Patients; Evaluation in Relation to Food Intake Ongoing in Proof-of-Concept CAD Study, Update Expected by Year-end 2025 $227 Million i

    8/14/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Bolsters Ophthalmology Expertise with Appointment of Retina Specialist Lloyd Clark, M.D., as Pivotal ANX007 Program Advances in Dry Age-Related Macular Degeneration (AMD) with Geographic Atrophy (GA)

    Dr. Clark Brings 25 Years of Experience Treating Retina Diseases and Developing Emerging Therapies as a Principal Investigator in Over 70 Clinical Trials and as an Early Pioneer of VEGF Inhibitors ANX007 is the Only Investigational Program Shown to Significantly Preserve Vision and Central Retinal Photoreceptors Critical for Visual Acuity Enrollment of Phase 3 ARCHER II Trial Expected to be Completed in Q3 2025, with Topline Data Expected in Second Half of 2026 BRISBANE, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-medi

    6/18/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors

    Aviceda Therapeutics ("Aviceda"), a private, clinical-stage biotech company focused on developing next-generation immunomodulators incorporating its proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform with an aim to alleviate chronic, non-resolving inflammation, today announced the appointment of Emmett T. Cunningham Jr., M.D., Ph.D., M.P.H. to its Board of Directors. Dr. Cunningham brings more than two decades of experience as a physician-scientist, healthcare entrepreneur, and investor. He was previously a Senior Managing Director at the Blackstone Group following its acquisition of Clarus Ventures, where he was a Managing Director. Throughout his investment car

    4/9/25 7:00:00 AM ET
    $ANNX
    $LUMO
    $GRAY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Financials

    Live finance-specific insights

    View All

    Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones

    Late-Stage Neuroinflammation Platform Advancing Global Registrational Programs in Guillain-Barré Syndrome (GBS) and Geographic Atrophy (GA) Current Tanruprubart GBS Dossier On Track for MAA Filing in January 2026; Potential to Be the First Approved Targeted and Fast-Acting Therapy for the Treatment of GBS; Continued FDA Discussions Regarding Generalizability Package in Support of BLA Filing Topline ARCHER II Pivotal Data for Vonaprument in Dry AMD with GA on Track for Second Half of 2026; Potential to Be the First Approved Vision Sparing Therapy for the Treatment of Eight Million GA Patients Worldwide ANX1502 Cold Agglutinin Disease (CAD) Proof of Concept Study Ongoing with Expected 2026

    11/10/25 4:05:00 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barré Syndrome (GBS)

    Real-World Evidence Study Strengthens the Body of Evidence Supporting ANX005 for Treatment of GBS ANX005 Phase 3 Population Was Matched 1:1 on Prespecified Criteria with Patients in International GBS Outcomes Study (IGOS) Matched Cohort Study Showed Early and Greater Benefits of ANX005 over IVIg or PE in Muscle Strength and Functional Outcomes Across Multiple Measurements Conference Call and Webcast Today at 8:30 a.m. ET BRISBANE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage clinical platform of novel therapies for people living with devastating classical complement-mediated neuroinflammatory diseases of the

    12/16/24 7:30:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome

    Single Infusion of ANX005 30 mg/kg Met Primary Endpoint, Delivering a Highly Statistically Significant and Clinically Meaningful 2.4-fold Improvement in GBS-DS vs. Placebo at Week 8, p=0.0058 ANX005 Demonstrated Early and Sustained Improvements in Key Secondary Endpoints Including Muscle Strength, Nerve Damage and Ventilation ANX005 Displayed Rapid Target Engagement and was Generally Well-Tolerated Across Doses Real-World Evidence (RWE) Comparability Data Expected in First Half 2025 Conference call and webcast today at 8:30 a.m. ET BRISBANE, Calif., June 04, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing a late-stage platform of novel ther

    6/4/24 7:00:00 AM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ANNX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 5:30:27 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care